Drug Trial Radar · NCT05597735
Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease
Last checked: Nov 19, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
480
Planned (sponsor's estimate)
Start
Mar 3, 2023
Primary completion
Sep 30, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- ANRS, Emerging Infectious DiseasesGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- University Hospital, Geneva; Oswaldo Cruz Foundation; Fundacion Huesped, Buenos Aires, Argentina
- First posted
- Oct 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall purpose of this study is to evaluate whether tecovirimat is an efficient and safe antiviral in the treatment of monkeypox in adults and adolescents (14 years old and older). The primary objective is to evaluate the clinical efficacy, as assessed by time to all visible lesion(s) resolution, of tecovirimat treatment + Standard of Care (SOC) compared to placebo + SOC for patients with monkeypox. The secondary objective is to evaluate the clinical efficacy, as assessed by mortality, hospitalization, complications, duration of symptoms and virological shedding, and the safety of tecovirimat treatment + SOC compared to placebo + SOC in patients with monkeypox.
Conditions
- Monkeypox
- Mpox
Interventions
TecovirimatDrug
The experimental intervention is tecovirimat, available as immediate-release capsules containing tecovirimat monohydrate, equivalent to 200 mg of tecovirimat. The route of administration of tecovirimat is oral. Tecovirimat treatment will be initiated as soon as possible after diagnosis. The international recommended doses will be followed: * 25 kg to less than 40 kg: 400 mg (two tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days. * 40 kg and above: 600 mg (three tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days.
PlaceboDrug
The control intervention is a placebo and its route of administration will be identical to the experimental intervention administration to allow treatment arm blinding.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to all visible lesion(s) resolutionTime frame: 28 days
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
Fundación Huésped
Buenos Aires, Argentina
Faculty of Medicine, Federal University of Minas Gerais
Belo Horizonte, Brazil
Evandro Chagas National Institute of Infectious Diseases-Oswaldo Cruz Foundation-FIOCRUZ
Rio de Janeiro, Brazil
Federal Hospital for State Employees
Rio de Janeiro, Brazil
Nova Iguaçu General Hospital
Rio de Janeiro, Brazil
University Hospital Prof. Edgard Santos
Salvador, Brazil
Emílio Ribas Institute of Infectious Diseases
São Paulo, Brazil
STD/AIDS Reference and Training Center
São Paulo, Brazil
Hôpitaux Universitaires de Genève
Geneva, Canton of Geneva, Switzerland
Pr Alexandra Calmy
Geneva, Canton of Geneva, Switzerland
CHUV
Lausanne, Canton of Vaud, Switzerland
Zürich checkpoint
Zurich, Canton of Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.